Efferon raised 2.5 million EUR in a seed funding round led by private investors from the DACH region. The funding will support the European commercial expansion of Efferon LPS, construction of a new EU production facility, and expansion of manufacturing capacity to meet growing demand for its blood purification therapy for sepsis and septic shock.
About Efferon
Biotech company developing multimodal hemoadsorption therapeutic devices designed to remove endotoxins and inflammatory mediators from the bloodstream for the treatment of sepsis, septic shock and other inflammation-related conditions.
Villach, Austria
Read Company ProfileFrequently Asked Questions
What type of funding round did Efferon raise?
Efferon raised a seed round.
How much did Efferon raise in its seed?
Efferon raised $2,500,000 EUR in its seed.
Who invested in Efferon's seed?
The investors in Efferon's seed are: Private investors from the DACH region.
What type of investment was Efferon's seed?
Efferon's seed was a equity investment.
How will Efferon use the funds from its seed?
Efferon plans to use the funds for: European commercial expansion of Efferon LPS, construction of a new EU production facility for Efferon LPS, expansion of manufacturing capacity.